我要投票 以岭药业在中草药行业中的票数:711
· 外 推 电 报 ·
2026-01-15 08:01:20 星期四

【以岭药业是哪个国家的品牌?】

以岭药业是什么牌子?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力以岭药业品牌出海!将品牌入驻外推网,定制以岭药业品牌推广信息,可以显著提高以岭药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

英文翻译:Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://www.waitui.com/brand/887854f10.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

跨境ETF规模总量突破万亿,25只跨境ETF规模超百亿元

随着全球资本市场共振上涨,资金对海外市场的热情也助推跨境ETF规模持续攀新高。据统计,截至1月13日,跨境ETF规模总量达到10098亿元人民币,这也是其历史上首次突破万亿元大关。拉长时间来看,2025年初跨境ETF规模为4242亿元,这意味着一年多的时间里,这类产品的总体规模增幅高达138%。在席卷全球的人工智能和创新药投资热潮下,多个主要市场在去年创下历史新高。因额度限制,资金的涌入也使得多只跨境ETF二级市场面临溢价,限购亦成为QDII基金的共有“标签”。整体来看,共有25只跨境ETF规模超百亿元,而在去年初,规模超百亿元的跨境ETF只有11只。(证券时报)

2分钟前

部分基金通过限购或暂停申购方式平衡规模与策略执行空间

近期,随着市场行情连续上涨,资金开始涌入,部分绩优权益基金相继采取暂停申购或限购等措施来“降温”,引发市场关注。从具体表现看,部分业绩持续走强、规模快速扩张的产品选择“闭门谢客”,以控制规模、保障运作稳定;亦有基金在主题行情升温、资金短期集中流入的背景下,通过阶段性限购调节申购节奏。从更深层次看,基金申购调整的背后,既反映了管理人对业绩持续性与规模约束的综合考量,也体现了对阶段性行情演绎与资金流入节奏的判断。在市场情绪回暖、热点赛道轮动加快的背景下,部分基金通过限购或暂停申购方式平衡规模与策略执行空间,相关安排也在一定程度上为后市行情的持续性提供了观察窗口。(证券时报)

2分钟前

招商证券:落后产能有望出清,化工行业盈利能力或迎来边际改善

36氪获悉,招商证券研报表示,2021年以来,受化工产品价格高景气度影响,石化和化工企业规划较多资本开支,开启新一轮产能扩张。2022年以来随着新增产能陆续投放,叠加原油价格自高位回落,大部分化工产品价格持续下跌,造成部分化工产品价格持续下跌,国内企业为了争夺市场份额,实行以价换量策略,导致整体盈利水平下降。2024年以来,多数化工品价格底部盘整,企业盈利水平仍处于承压状态,随着后续稳增长工作方案的出台,招商证券认为部分落后产能有望被淘汰,行业整体供需格局将发生边际改善,产品盈利能力有望提高。

2分钟前

0费率理财产品涌现,机构盯上万亿存款搬家蛋糕

2026年伊始,银行理财公司降费潮再度升级,0费率、超低费率产品涌现。国有大行、股份制银行及城商行系理财公司集体发力,通过阶段性下调固定管理费、销售服务费等方式抢占市场,目标直指持续释放的存款搬家资金。业内人士认为,价格优惠虽能实现短期冲量,但长期发展终究要靠理财公司的核心竞争力。机构切忌陷入单纯的价格战,必须从多维度打造差异化优势。(中证报)

2分钟前

有色金属主题基金成机构“新宠”

有色金属正在成为机构发力布局的重点。从产品情况看,近一周以来,有7只有色金属主题基金集中上报,还有多只有色金属主题基金正在或是即将发行。从资金流向看,过去一年来,有色金属主题ETF(剔除黄金主题)净申购额超过510亿元,15只有色金属主题ETF最新规模近800亿元。据中国证监会官网显示,1月13日,工银瑞信中证有色金属矿业主题ETF、中银中证工业有色金属主题ETF、兴业中证工业有色金属主题指数基金集中上报。自今年1月7日以来,已有7只有色金属主题基金上报。(上证报)

2分钟前

本页详细列出关于以岭药业的品牌信息,含品牌所属公司介绍,以岭药业所处行业的品牌地位及优势。
咨询